(Q40836669)

24 September 2017

Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation (English)

1 reference

24 September 2017

1 reference

Colletier PJ

1

1 reference

24 September 2017

Ashoori F

2

1 reference

24 September 2017

Cowen D

3

1 reference

24 September 2017

Meyn RE

4

1 reference

24 September 2017

Tofilon P

5

1 reference

24 September 2017

Meistrich ME

6

1 reference

24 September 2017

Pollack A

7

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

International Journal of Radiation Oncology Biology Physics

24 September 2017

1 reference

24 September 2017

48

1 reference

24 September 2017

1507-1512

1 reference

24 September 2017

5

1 reference

Radiation-induced apoptosis: relevance to radiotherapy

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

p53 is required for radiation-induced apoptosis in mouse thymocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Safety evaluation of Ad5CMV-p53 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Radical prostatectomy for high grade disease: a reevaluation 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

Combined radiation and p53 gene therapy of malignant glioma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2901409-7

7 January 2021

10.1016/S0360-3016(00)01409-7

Identifiers

DOI

1 reference

24 September 2017

1 reference